JP2021517566A5 - - Google Patents
Info
- Publication number
- JP2021517566A5 JP2021517566A5 JP2020547406A JP2020547406A JP2021517566A5 JP 2021517566 A5 JP2021517566 A5 JP 2021517566A5 JP 2020547406 A JP2020547406 A JP 2020547406A JP 2020547406 A JP2020547406 A JP 2020547406A JP 2021517566 A5 JP2021517566 A5 JP 2021517566A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023209816A JP7673168B2 (ja) | 2018-03-14 | 2023-12-13 | 汎発性膿疱性乾癬の処置のための抗ｉｌ－３６ｒ抗体の使用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642641P | 2018-03-14 | 2018-03-14 | |
| US62/642,641 | 2018-03-14 | ||
| US201862683720P | 2018-06-12 | 2018-06-12 | |
| US62/683,720 | 2018-06-12 | ||
| US201862699274P | 2018-07-17 | 2018-07-17 | |
| US62/699,274 | 2018-07-17 | ||
| US201862729518P | 2018-09-11 | 2018-09-11 | |
| US62/729,518 | 2018-09-11 | ||
| PCT/US2019/021335 WO2019177888A1 (en) | 2018-03-14 | 2019-03-08 | Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023209816A Division JP7673168B2 (ja) | 2018-03-14 | 2023-12-13 | 汎発性膿疱性乾癬の処置のための抗ｉｌ－３６ｒ抗体の使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021517566A JP2021517566A (ja) | 2021-07-26 |
| JPWO2019177888A5 JPWO2019177888A5 (https=) | 2023-03-23 |
| JP2021517566A5 true JP2021517566A5 (https=) | 2023-03-23 |
| JP7404256B2 JP7404256B2 (ja) | 2023-12-25 |
Family
ID=65904556
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547406A Active JP7404256B2 (ja) | 2018-03-14 | 2019-03-08 | 汎発性膿疱性乾癬の処置のための抗ｉｌ－３６ｒ抗体の使用 |
| JP2023209816A Active JP7673168B2 (ja) | 2018-03-14 | 2023-12-13 | 汎発性膿疱性乾癬の処置のための抗ｉｌ－３６ｒ抗体の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023209816A Active JP7673168B2 (ja) | 2018-03-14 | 2023-12-13 | 汎発性膿疱性乾癬の処置のための抗ｉｌ－３６ｒ抗体の使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20190284285A1 (https=) |
| EP (1) | EP3765513A1 (https=) |
| JP (2) | JP7404256B2 (https=) |
| KR (1) | KR102768040B1 (https=) |
| CN (1) | CN112272674A (https=) |
| AU (1) | AU2019236105B2 (https=) |
| BR (1) | BR112020016738A2 (https=) |
| CA (1) | CA3093692A1 (https=) |
| CL (1) | CL2020002342A1 (https=) |
| IL (1) | IL277215B2 (https=) |
| MX (1) | MX2020009544A (https=) |
| PH (1) | PH12020551444A1 (https=) |
| WO (1) | WO2019177888A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016168542A1 (en) | 2015-04-15 | 2016-10-20 | Anaptysbio, Inc. | Antibodies directed against interleukin 36 receptor (il-36r) |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CA3093692A1 (en) | 2018-03-14 | 2019-09-19 | Boehringer Ingelheim International Gmbh | Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis |
| MX2021000566A (es) | 2018-07-16 | 2021-06-23 | Regeneron Pharma | Anticuerpos anti-il36r. |
| EP3902604A1 (en) * | 2018-12-27 | 2021-11-03 | Boehringer Ingelheim International GmbH | Anti-il-36r antibodies for treatment of palmoplantar pustulosis |
| BR112021016198A2 (pt) * | 2019-03-08 | 2021-11-03 | Boehringer Ingelheim Int | Formulações de anticorpo anti-il-36r |
| EP4182022A1 (en) * | 2020-07-17 | 2023-05-24 | Boehringer Ingelheim International GmbH | Anti-il-36r antibodies for the treatment of neutrophilic dermatoses |
| WO2022026829A1 (en) * | 2020-07-30 | 2022-02-03 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity |
| JP2023536851A (ja) * | 2020-07-30 | 2023-08-30 | アナプティスバイオ インコーポレイティッド | 魚鱗癬のための抗インターロイキン３６受容体（ｉｌ－３６ｒ）療法 |
| CN121324515A (zh) * | 2020-09-16 | 2026-01-13 | 上海市皮肤病医院 | 基于代谢组学的泛发性脓疱型银屑病诊断标志物及其应用 |
| US20220119538A1 (en) * | 2020-09-30 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Anti-il-36r antibodies for treatment of chronic inflammatory pain |
| WO2022166977A1 (zh) * | 2021-02-08 | 2022-08-11 | 上海普铭生物科技有限公司 | 抗人il-36r抗体及其应用 |
| CA3209006A1 (en) * | 2021-03-04 | 2022-09-09 | Boehringer Ingelheim International Gmbh | Methods for the treatment of gpp |
| WO2022192531A2 (en) * | 2021-03-12 | 2022-09-15 | Boehringer Ingelheim International Gmbh | Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis |
| CA3218343A1 (en) * | 2021-05-12 | 2022-11-17 | Anaptysbio, Inc. | Antibody composition |
| CN113274494B (zh) * | 2021-06-07 | 2022-09-20 | 武汉生物制品研究所有限责任公司 | 一种抗SARS-CoV-2的重组全人源单克隆抗体的液体制剂 |
| CN115327130A (zh) * | 2022-07-25 | 2022-11-11 | 深圳市妇幼保健院 | 一种免疫生物标志物在制备小儿脓毒血症诊断试剂盒中的应用 |
| CN115724975A (zh) * | 2022-10-20 | 2023-03-03 | 江苏荃信生物医药股份有限公司 | 抗人白介素36受体单克隆抗体及其应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| EP0999853B1 (en) | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
| ES2274574T3 (es) | 1997-08-01 | 2007-05-16 | Schering Corporation | Proteinas de membrana celular de mamifero; reactivos relacionados. |
| US6416973B1 (en) | 1997-08-01 | 2002-07-09 | Schering Corporation | Nucleic acids encoding mammalian cell membrane protein MDL-1 |
| DE19733389C2 (de) | 1997-08-01 | 1999-08-19 | Deutsches Krebsforsch | Mittel zur Expression und zum Nachweis eines ein HPOL-Epitop und ein Polypeptid enthaltenden Fusionspolypeptids |
| CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| EP1627927A3 (en) | 2001-03-01 | 2006-06-07 | Epigenomics AG | Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA |
| EP1556403A4 (en) | 2002-10-03 | 2006-06-28 | Large Scale Biology Corp | MAKING MULTIMETER PROTEINS |
| CN1798575A (zh) | 2003-04-04 | 2006-07-05 | 健泰科生物技术公司 | 高浓度抗体和蛋白制剂 |
| US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP1977007A4 (en) * | 2005-12-28 | 2009-11-11 | Centocor Ortho Biotech Inc | MARKERS AND METHOD FOR THE ASSESSMENT AND TREATMENT OF PSORIASIS AND RELATED DISEASES |
| MX2009002456A (es) | 2006-09-08 | 2009-03-20 | Amgen Inc | Variantes de la familia il-1. |
| CA2685015A1 (en) | 2007-04-23 | 2008-11-06 | Schering Corporation | Anti-mdl-1 antibodies |
| US20100221252A1 (en) | 2007-06-29 | 2010-09-02 | Schering Corporation | Mdl-1 uses |
| WO2009040602A1 (en) | 2007-09-25 | 2009-04-02 | Becton Dickinson France | Autoinject0r with deactivating means moveable by a safety shield |
| US9124378B2 (en) | 2007-10-06 | 2015-09-01 | The Nielsen Company (Us), Llc | Gathering research data |
| US20110159011A1 (en) | 2008-08-28 | 2011-06-30 | Wyeth Llc | Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases |
| WO2011026948A1 (en) | 2009-09-03 | 2011-03-10 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| US20120121580A1 (en) | 2009-07-28 | 2012-05-17 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| HRP20181598T1 (hr) | 2010-06-03 | 2018-11-30 | Abbvie Biotechnology Ltd | Uporaba i pripravci za liječenje hidradenitis suppurativa (hs) |
| KR102038310B1 (ko) * | 2011-11-16 | 2019-11-01 | 베링거 인겔하임 인터내셔날 게엠베하 | 항 ｉｌ-36ｒ 항체 |
| AU2013212587B2 (en) | 2012-01-23 | 2017-07-20 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-Ang2 antibodies |
| CH705992A2 (de) | 2012-10-11 | 2013-06-14 | Tecpharma Licensing Ag | Injektionsvorrichtung. |
| EP4223312A1 (en) * | 2013-08-15 | 2023-08-09 | Novartis AG | Methods of treating plaque psoriasis using il-17 antagonists |
| DK3194583T3 (da) | 2014-07-30 | 2021-12-20 | Zumutor Biologics Inc | Ikke-fucosyleret protein og fremgangsmåder dermed |
| CN105330740B (zh) | 2014-07-30 | 2018-08-17 | 珠海市丽珠单抗生物技术有限公司 | 抗pd-1抗体及其应用 |
| CA2874083C (en) | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| WO2016168542A1 (en) * | 2015-04-15 | 2016-10-20 | Anaptysbio, Inc. | Antibodies directed against interleukin 36 receptor (il-36r) |
| CN107660155B (zh) | 2015-04-24 | 2021-02-02 | 艾斯曲尔医疗公司 | 药剂输送装置的子组件和药剂输送装置 |
| CH711066A2 (de) | 2015-05-13 | 2016-11-15 | Tecpharma Licensing Ag | Verbesserte Injektionsvorrichtung. |
| CN106470162B (zh) | 2015-08-19 | 2019-06-25 | 中国移动通信集团公司 | 一种业务报文的组播方法及装置 |
| JP6654773B2 (ja) | 2015-12-25 | 2020-02-26 | 国立大学法人名古屋大学 | インターロイキン３６受容体アンタゴニスト欠損症の治療薬 |
| HRP20250951T1 (hr) | 2015-12-30 | 2025-10-10 | F. Hoffmann-La Roche Ag | Formulacije sa smanjenom razgradnjom polisorbata |
| JP2020512344A (ja) | 2017-03-27 | 2020-04-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗ｉｌ−３６ｒ抗体併用治療 |
| CN107362351B (zh) | 2017-09-04 | 2020-11-10 | 上海市儿童医院 | Il-36r的拮抗剂在制备镇痛药物中的应用 |
| CA3093692A1 (en) | 2018-03-14 | 2019-09-19 | Boehringer Ingelheim International Gmbh | Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis |
| AU2019234478A1 (en) | 2018-03-14 | 2020-08-20 | Boehringer Ingelheim International Gmbh | Use of anti-IL36R antibodies for treatment of inflammatory bowel disease |
| MX2021000566A (es) | 2018-07-16 | 2021-06-23 | Regeneron Pharma | Anticuerpos anti-il36r. |
| IL278267B2 (en) | 2018-07-16 | 2025-02-01 | Regeneron Pharma | Non-human animal models of DITRA disease and their uses |
| EP3902604A1 (en) | 2018-12-27 | 2021-11-03 | Boehringer Ingelheim International GmbH | Anti-il-36r antibodies for treatment of palmoplantar pustulosis |
| BR112021016198A2 (pt) | 2019-03-08 | 2021-11-03 | Boehringer Ingelheim Int | Formulações de anticorpo anti-il-36r |
| KR102708558B1 (ko) | 2019-06-20 | 2024-09-24 | 삼성전자주식회사 | 수직형 메모리 장치 |
| WO2021087245A1 (en) | 2019-10-30 | 2021-05-06 | The Texas A&M University System | Protease switch for dual targets chimeric antigen receptor t cell therapy |
| EP4182022A1 (en) | 2020-07-17 | 2023-05-24 | Boehringer Ingelheim International GmbH | Anti-il-36r antibodies for the treatment of neutrophilic dermatoses |
| US20220119538A1 (en) | 2020-09-30 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Anti-il-36r antibodies for treatment of chronic inflammatory pain |
-
2019
- 2019-03-08 CA CA3093692A patent/CA3093692A1/en active Pending
- 2019-03-08 US US16/296,825 patent/US20190284285A1/en not_active Abandoned
- 2019-03-08 BR BR112020016738-0A patent/BR112020016738A2/pt unknown
- 2019-03-08 KR KR1020207029378A patent/KR102768040B1/ko active Active
- 2019-03-08 IL IL277215A patent/IL277215B2/en unknown
- 2019-03-08 EP EP19713267.3A patent/EP3765513A1/en active Pending
- 2019-03-08 MX MX2020009544A patent/MX2020009544A/es unknown
- 2019-03-08 CN CN201980019232.2A patent/CN112272674A/zh active Pending
- 2019-03-08 JP JP2020547406A patent/JP7404256B2/ja active Active
- 2019-03-08 AU AU2019236105A patent/AU2019236105B2/en active Active
- 2019-03-08 WO PCT/US2019/021335 patent/WO2019177888A1/en not_active Ceased
-
2020
- 2020-09-10 CL CL2020002342A patent/CL2020002342A1/es unknown
- 2020-09-11 PH PH12020551444A patent/PH12020551444A1/en unknown
- 2020-11-23 US US17/101,126 patent/US12503512B2/en active Active
-
2023
- 2023-12-13 JP JP2023209816A patent/JP7673168B2/ja active Active